New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:09 EDTVRTXVertex presents new Phase 3 data on HCV treatment with twice-daily telaprevir
Vertex Pharmaceuticals announced that new data from a Phase 3 study in people being treated for hepatitis C for the first time showed similar rates of viral cure (SVR12, HCV RNA levels < 25 IU/mL 12 weeks after the end of all treatment) when telaprevir was given twice daily compared to three times daily, the currently approved dosing schedule. Telaprevir is approved for use in combination with pegylated-interferon and ribavirin by the U.S. Food and Drug Administration, FDA, and Health Canada under the brand name INCIVEK® (telaprevir) tablets for people with genotype 1 chronic hepatitis C virus, HCV, with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver). In addition, new data from a Phase 2 study demonstrated that approximately three of four people co-infected with HCV and HIV achieved an HCV viral cure (SVR24, HCV RNA levels < 25 IU/mL 24 weeks after the end of all treatment) with telaprevir combination treatment. These and other new data on Vertex’s medicines in development for hepatitis C were presented at The Liver Meeting®, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, AASLD.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
16:28 EDTVRTXOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:51 EDTVRTXVertex expects payers to provide 'broad access' for Orkambi
Subscribe for More Information
14:50 EDTVRTXVertex to resume trading at 3:00 PM ET
Subscribe for More Information
14:42 EDTVRTXVertex says 'too early to comment' on international Orkambi pricing
Subscribe for More Information
14:33 EDTVRTXVertex sets Orkambi price at $259,000, sees delivery to pharmacies 'within days'
Following today's confirmation from Vertex that Orkambi has received FDA approval, the company held a conference call providing an update on the drug. Vertex remarked that it is "ready to launch this medicine." Vertex will offer a co-pay assistance program for the drug, with certain eligibility criteria. Company believes it can achieve a similar patient cost situation as Kalydeco. Sets price of Orkambi at $259,000 per year. Expects delivery to pharmacy network "within days."
13:52 EDTVRTXVertex to hold a conference call
Subscribe for More Information
13:47 EDTVRTXVertex confirms FDA approval of ORKAMBI
Vertex Pharmaceuticals announced that the U.S. FDA approved ORKAMBI, the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test. People with two copies of the F508del mutation represent the largest group of people with CF. Of the 30,000 people in the United States with CF, approximately 8,500 ages 12 and older have two copies of the F508del mutation. ORKAMBI will be available for shipment to specialty pharmacies in the United States within days.
12:47 EDTVRTXVertex to return to profitability with approval, says Piper Jaffray
Subscribe for More Information
12:00 EDTVRTXVertex receives FDA approval for Orkambi
Subscribe for More Information
11:50 EDTVRTXVertex trading halted, pending news
Subscribe for More Information
June 30, 2015
07:32 EDTVRTXVertex should get Orkambi approval by Monday or sooner, says Piper Jaffray
Subscribe for More Information
June 29, 2015
15:28 EDTVRTXVertex management to meet with UBS
Subscribe for More Information
07:47 EDTVRTXCerulean appoints Stuart A. Arbuckle to board of directors, effective June 26
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use